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Abstract
Introduction: Autoinflammatory diseases are characterized by seemingly unprovoked episodes of inflammation,
without high titers of autoantibodies or antigen-specific T cells, and derive from genetic variants of the innate
immune system. This study characterized a cohort of patients with similar phenotypes and nucleotide
oligomerization domain 2 (NOD2) gene mutations.
Methods: Diagnostically challenging patients with the following clinical and genetic characteristics were
prospectively studied between January 2009 and April 2011: periodic fever, dermatitis, polyarthritis, serositis,
negative serum autoantibodies and additional positive NOD2 IVS8
+158 gene mutation. Genetic testing for gene
mutations of NOD2, tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS) and familial
Mediterranean fever (FMF) was performed.
Results: All seven patients with the disease were Caucasians, with four being male. The mean age at disease onset
was 40.7 years and disease duration was 3.2 years. These patients characteristically presented with periodic fever,
dermatitis and inflammatory polyarthritis. There were gastrointestinal symptoms in three patients, granulomas of
the skin and gut in two, and recurrent chest pain in two, with one having pleuritis and pericarditis. Three patients
had sicca-like symptoms. Five patients had increased acute phase reactants. All seven patients had negative tests
for autoantibodies but carried the NOD2 gene mutation IVS8
+158 with four having concurrent R702W mutation.
Conclusions: Our cohort may represent a new disease category of autoinflammatory disease with characteristic
clinical phenotypes and genotypes. It may somewhat resemble pediatric Blau’s syndrome.
Introduction
Autoinflammatory diseases (AIDs) were initially defined
as seemingly unprovoked episodes of inflammation,
without high titer autoantibodies or antigen specific T
cells [1]. It is recently proposed that the AIDs are clini-
cal disorders marked by abnormally increased inflamma-
tion, mediated predominantly by the cells and molecules
of the innate immune system, with a significant host
predisposition [2]. AIDs represent a wide disease spec-
trum, ranging from Mendalian disorders such as Blau’s
syndrome (BS) to a more complex (polygenic) mode of
inheritance such as Crohn’s disease [2]. In clinical prac-
tice, particularly in tertiary referral centers, physicians
may encounter various autoinflammatory phenotypes
which could cause highly costly and unnecessary repeti-
tive workups. We hypothesized these phenotypes could
be associated with unidentified gene mutations. Herein,
we report an adult case series with similar clinical phe-
notypes to support a novel AID entity associated with
positive nucleotide oligomerization domain (NOD2)
gene mutations.
Materials and methods
Patients
Seven diagnostically complex patients with symptoms of
multiple system involvement were referred to our Rheu-
matology Clinic at the Cleveland Clinic between January
2009 and April 2011. These adult patients had under-
gone extensive evaluations from multidisciplinary
departments. This prospective study was approved by
the Institutional Review Board.
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In addition to routine blood tests, all patients also had
special tests for systemic autoimmune diseases includ-
ing, but not limited to, classic connective tissue diseases
and systemic vasculitis. The serum autoantibodies tested
included antinuclear antibodies, anti-extractable nuclear
antigen (Sm, RNP, SSA, SSB, Scl70, centromere, Jo-1
and chromatin) antibodies, rheumatoid factor, anti-
citrullinated peptide antibodies, anti-dsDNA antibodies,
complements 3 and 4, lupus anticoagulant, anti-cardioli-
pin antibodies, anti-beta2glyprotein I antibodies and
anti-neutrophil cytoplasmic antibodies.
Since these patients were clinically suspected of auto-
inflammatory diseases, such as BS, blood specimens of
the patients were sent and genetically tested by the Cen-
ter for Genetic Testing in Saint Francis, Oklahoma, USA
for NOD2 gene mutations after informed consent was
obtained. Examination of the NOD2 gene for mutations
was performed by DNA polymerase chain reactions and
DNA sequencing of all 12 coding exons. In addition,
genetic testing for tumor necrosis factor receptor asso-
ciated periodic fever syndrome (TRAPS) and familial
Mediterranean fever (FMF) was also conducted in some
cases as clinically appropriate (GeneDx, Gaithersburg,
Maryland, USA).
Inclusion and exclusion criteria
The inclusion clinical criteria were patients having 1)
periodic fever, which was defined as episodic fever of
unknown origin two or more times during the disease
process; 2) dermatitis; 3) polyarthritis; 4) serositis; and
5) absence of any autoantibodies. The disease entity was
considered to be present if three or more criteria were
met plus additional positive NOD2 IVS8
+158 gene muta-
tion. We also excluded systemic autoimmune diseases
and other AIDs.
Outcome measurement
Demographics, and clinical and genetic features of the
patients were characterized. Descriptive statistics were
used.
Results
A total of seven patients were included in the study. All
were Caucasians, with four being men (57.1%). The
mean age at disease onset was 40.7 years (range 21 to
60 years) and disease duration was 3.2 years (range 1 to
8 years). No family history of any AIDs was reported.
Constitutional symptoms
Constitutional symptoms included flu-like symptoms,
significant weight loss and fatigue. Five patients had per-
iodic fevers with each episode lasting a few days to sev-
eral weeks and varying afebrile intervals. Table 1
summarizes the demographic, clinical and genotypic fea-
tures of the seven patients.
Cutaneous presentation
Six of the seven patients had skin disease presented with
pruritic or nonpruritic erythematous edematous plaques,
patches, macules, papules and linear scratch-like rash in
the face (Figure 1A), chest, abdomen and limbs. Among
these patients, two had spongiotic dermatitis, with
superficial perivascular lymphohistocytic (Patient 1),
lymphoplasmacytic infiltrate (Patient 2, Figure 1B), and
Patient 5 had mixed lymphocytic and neutrophilic pari-
vascular dermatitis. Patient 3 had perivascular and
mixed inflammatory infiltrate which consisted of numer-
ous activated histocytes forming ill-defined granulomas
and rare associated multinucleated cells, consistent with
palisaded neutrophilic and granulomatous dermatitis
(Figure 1C, D). There were capillaritis without evidence
of vasculitis (Patient 4) and oral ulcers (Patient 6).
Inflammatory arthritis
Multiple joint pain, tenderness and swelling were com-
mon and the arthritis was non-erosive. Polyarthralgia
can affect nearly any joints in the limbs, particularly the
hip, knee and ankle. Hip symptoms were prominent in
three cases. Patient 3 underwent bilateral total hip repla-
cement in her 40s presumably due to osteoarthritis.
Gastrointestinal (GI) manifestation
Three patients presented with intermittent GI symp-
toms, such as abdominal pain and/or diarrhea, but with-
out radiographic, endoscopic or histologic evidence of
Crohn’s disease. Patient 4 presented with recurrent
fever, abdominal pain without diarrhea and abnormal
liver enzymes and was found to have mild colitis in the
cecum and sigmoid colon, with gastric and colonic non-
necrotizing granulomas. A computerized tomography
(CT) scan and positron emission tomography scan
showed numerous enlarged mesenteric lymph nodes,
histologically consistent with granulomatous lymphade-
nitis. Patient 6 developed two episodes of abdominal
pain and nausea with transient lipasemia suspicious of
acute idiopathic pancreatitis.
Cardiopulmonary manifestations
Patient 6 also complained of recurrent chest pain with
negative cardiopulmonary and GI workups. Patient 7
had recurrent chest pain associated with pleuritis on
chest radiographs and pericarditis on echocardiography.
Ophthalmic and neurological manifestations
Three of the patients complained of blurry vision and
dry eyes but ophthalmologic examination revealed cen-
tral scotoma of both eyes, right eye episcleritis and a
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was no uveitis found in these three patients. These
sicca-like symptoms prompted a workup for Sjögren’s
syndrome but antinuclear antibodies, anti-SSA/anti-SSB
antibodies and minor salivary gland biopsies all were
negative. Neurological symptoms included headaches in
three cases but with an unremarkable neurological
examination. One patient (Patient 2) presented with
paresthesias of the extremities and later was found to
have small fiber sensory neuropathy.
Laboratory and genetic testing results
Patient 1 had mild anemia, leukocytosis and eosinophi-
lia. Five patients had elevated acute phase reactants. The
special tests for systemic autoimmune diseases were
negative as stated in the methods. Urinalysis was nega-
tive in all patients and chest radiographs and CT were
negative in all but Patient 7. Two patients (Patients 1
a n d4 )u n d e r w e n th e m a t o l o g i c a le v a l u a t i o nb u tw i t h
normal results. All seven patients were confirmed to
carry the NOD2 gene mutations, including IVS8
+158 in
all patients and R702W in four (Table 1). Patients 2, 4,
5, 6 and 7 also had negative gene testing for TRAPS
and/or FMF.
Therapy and outcomes
Our patients were empirically treated with nonsteroidal
antiinflammatory drugs (NSAIDs), prednisone, hydroxy-
chloroquine and TNF-a blockers. NSAIDs appeared
ineffective for arthritic manifestation, which responded
to a low dose prednisone (< 20 mg daily). Two of the
patients were taking sulfasalazine two to three grams
daily for arthritis for 3 to 12 months with minimal
improvement. One patient continued to have bilateral
hip pain despite taking a small dose prednisone, sulfasa-
lazine and methotrexate. The patients with skin disease
responded to prednisone but not to hydroxychloroquine.
Table 1 Demographic, clinical and subclinical features of seven patients
Patient 1 2 3 4 5 6 7
Gender Male Female Female Male Female Male Male
Age at diagnosis (years) 41 45 53 28 62 37 40
Disease duration(years) 1 1 8 7 2 2 1
Ethnicity White White White White White White White
Weight loss Yes Yes No Yes Yes Yes Yes
Fever Yes No No Yes Yes No Yes
Skin disease Yes Yes Yes Yes Yes Yes No
Polyarthritis Yes Yes Yes No Yes Yes No
Serositis No No No No No Chest pain Pleuritis/pericarditis
Ocular Normal Blurry,
dry
Blurry,
dry
Normal Normal Pain and redness,
dry
No
Gastrointestinal Normal Pain, diarrhea Normal Pain Normal Pain and diarrhea, lipasemia Elevated LFT
a
Familial No No No No No No No
ESR
b (mm/hr) 61 5 60 92 10 2 74
CRP
c (mg/dl) 7.5 NA
d 17.9 7.2 12.3 Normal 38.7
NOD2
e IVS8+
158
C>T ,
R702W
IVS8+
158
C>T ,
R702W
IVS8+
158
C>T
IVS8+
158
C>T
IVS8+
158
C>T ,
R702W
IVS8+
158
C>T
R702W
IVS8+
158
C>T
TRAPS
f NA Negative NA Negative Negative Negative Negative
MEFV
g NA NA NA NA Negative NA Negative
aLiver enzymes;
berytherocyte sedimentation rate;
cc-reactive protein;
dnot available;
enucleotide oligomerization domain;
ftumor necrosis factor receptor
associated periodic fever syndrome;
gMediterranean fever
Figure 1 Skin manifestation. Erythematous edematous plaques in
Patient 2 (A), subacute spongiotic dermatitis in Patient 2 (B), 40×,
granulomatous dermatitis in Patient 3 (C and D), Hematoxylin and
eosin, 20× and 40×.
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respond to colchicine or NSAIDs but responded to high
dose prednisone. One patient was treated with TNF-a
blockers (infliximab and adalimumab) with a partial
response for inflammatory arthritis and fevers. Among
the three patients with GI symptoms, one (Patient 4)
continued to have intermittent abdominal pain and the
other two had no abdominal pain and diarrhea recently.
Discussion
AIDs are characterized by seemingly unprovoked epi-
sodes of inflammation, without high titer autoantibodies
or antigen specific T cells, and derive from genetic var-
iants of the innate immune system, including Mendalian
and genetically complex disorders [1]. The disease entity
we describe in the present paper consists of periodic
fevers, skin disease, inflammatory arthritis, serositis,
sicca-like symptoms and elevated acute phase reactants
but the hallmarks of autoimmunity are lacking, therefore
it is congruent with an AID. This constellation of clini-
cal phenotypes together with the NOD2 gene mutation
may constitute a variant of the AIDs. To our knowledge,
this disease entity does not fit any known AIDs. Given
its strong association with the gene mutation, we pre-
sently categorize and designate this disease as a new
AID. We believe that this condition may be underdiag-
nosed due to a lack of awareness of this clinical entity.
This disease entity could represent a polygenic disease
because it did not appear rare. This disorder seems
similar to pediatric BS in phenotypes and genotypes to
some extent, thus we will focus the following discussion
on a Blau’s-like syndrome as well as Crohn’s disease.
BS (MIM186580) is an autosomal dominant AID,
which was originally characterized by a triad of granulo-
matous dermatitis, arthritis and uveitis [3]. Currently,
BS and early onset sarcoid arthritis are accepted as the
same disease [4]. There have been over 154 cases of
pediatric BS reported, involving 41 families [5]. Other
manifestations include fevers, abnormal liver function
tests, large vessel arteritis, cranial neuropathy, pneumo-
nitis, lymphadenitis, sialadenitis, erythema nodosum
[5,6] and sinus of valsalva aneurysm [7]. To the best of
our knowledge, there have been no reports of adult
onset cases of BS. Our case series study demonstrates
that the clinical manifestations of this new adult disease
entity are partially within the reported clinical spectrum
of pediatric BS; however, the disease entity also differs
from pediatric BS in that the former may not present
with the classic triad of the pediatric form and has some
distinct clinical features as discussed below.
First, we found that periodic fevers, dermatitis and
polyarthralgias/inflammatory polyarthritis are common
in our case series but without deformity, Camptodactyly
(flexion contracture of the fingers and toes), that was
originally reported in the members of a single family by
Blau [3]. Second, while pediatric BS can present with a
variety of skin manifestations [5], our adult patients
showed predominantly non-granulomatous dermatitis
with occasional granulomas. Third, uveitis has been
reported in 61% (46/76) of the pediatric BS patients [8];
however, none of our patients had uveitis.
Among the seven patients, there were three cases of
GI symptoms which prompted an exhaustive search for
Crohn’s disease. One patient carried a history of ques-
tionable Crohn’s disease, but symptoms of periodic
fevers and skin disease with minimal evidence of active
Crohn’s disease would argue against the likelihood of
Crohn’s disease in this patient. Although granulomas are
known to occur in both Crohn’sd i s e a s ea n dB S[ 9 ] ,
non-granulomatous dermatitis as in our series is extre-
mely rare in Crohn’s disease [10]. Nevertheless, these
patients did not have cogent evidence of Crohn’sd i s -
ease. Therefore, an intermediate subset of the new AID
with Crohn’s disease-like presentation ought to be
entertained in these patients and Crohn’s disease should
be listed as a differential diagnosis.
The NOD2 gene mutations (chromosome 16q12-21)
have been principally linked to both Crohn’s disease and
BS [11-14]. To date, there are 105 NOD2 gene mutation
sequence variants reported [15]. NOD2 IVS8
+158 gene
mutation was initially reported to confer higher risk for
Crohn’s disease in Ashkenazi Jews [16]. Subsequently,
two available studies failed to replicate the association
between the gene mutation and Crohn’s disease in the
Ashkenazi Jews [17] and Jewish Israeli population [18].
None of our patients were Jewish. It is worth noting
that this gene mutation was not studied and reported in
pediatric BS until it was recently reported to associate
with the disease in a single case report where Borzutzky
A, et al. [19] described a nine-month-old Caucasian boy
who developed fever, migratory rash consistent with
cutaneous tuberculoid granulomas and inflammatory
arthritis. In conjunction with granulomatous panuveitis,
the patient was diagnosed with early onset sarcoidosis/
Blau’s syndrome, and the NOD2 gene mutation IVS8
+158 was found. In our series, the IVS8
+158 NOD2 gene
mutation was detected in all patients. Interestingly, four
patients with positive IVS8
+158 also carried the R702W
gene mutation. These findings suggest that the com-
bined IVS8
+158 and R702W gene mutations may confer
ah i g h e rr i s kf o rt h ec u r r e ntly described new AID. Of
note, there were cases of similar clinical presentations
with negative NOD2 gene mutations in our study. For
example, one adult case of Sjögren’ss y n d r o m ea n do n e
case of adult onset sarcoidosis without pulmonary invol-
vement had negative NOD2 gene mutations. To the best
of our knowledge, there have been no reports on the
involvement of IVS8
+158 in other diseases apart from
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presently propose that the gene mutation IVS8
+158 may
be entertained as a diagnostic marker for the new entity.
However, the clinical relevance of such gene mutations
to these diseases remains to be determined given the
limited studies. We anticipate more investigations, such
as analysis of haplotype frequency, DNA sequencing of
t h ee n t i r eg e n ea n dt h eg e n o t y p e - p h e n o t y p ec o r r e l a t i o n
in the new AID using genome wide association study.
Conclusions
Our adult case study suggests that the currently
described disease entity constitutes a new category of
AIDs, which phenotypically resembles the pediatric BS
cases and can mimic Crohn’s disease. Genotypically, the
IVS8
+158 NOD2 mutation appears associated with the
disease, particularly in conjunction with R702W. This
new disease entity may be genetically complex rather
than Mendalian.
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